PL2872139T3 - Kompozycja i sposób leczenia depresji i psychozy u ludzi - Google Patents
Kompozycja i sposób leczenia depresji i psychozy u ludziInfo
- Publication number
- PL2872139T3 PL2872139T3 PL13816622T PL13816622T PL2872139T3 PL 2872139 T3 PL2872139 T3 PL 2872139T3 PL 13816622 T PL13816622 T PL 13816622T PL 13816622 T PL13816622 T PL 13816622T PL 2872139 T3 PL2872139 T3 PL 2872139T3
- Authority
- PL
- Poland
- Prior art keywords
- psychosis
- humans
- depression
- treatment
- composition
- Prior art date
Links
- 208000020401 Depressive disease Diseases 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261741114P | 2012-07-12 | 2012-07-12 | |
| US201261741115P | 2012-07-12 | 2012-07-12 | |
| PCT/US2013/049653 WO2014011590A2 (en) | 2012-07-12 | 2013-07-09 | Composition and method for treatment of depression and psychosis in humans |
| EP13816622.8A EP2872139B1 (en) | 2012-07-12 | 2013-07-09 | Composition and method for treatment of depression and psychosis in humans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2872139T3 true PL2872139T3 (pl) | 2018-06-29 |
Family
ID=49914491
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17181057T PL3263108T3 (pl) | 2012-07-12 | 2013-07-09 | Kompozycja i sposób leczenia depresji i psychozy u ludzi |
| PL13816622T PL2872139T3 (pl) | 2012-07-12 | 2013-07-09 | Kompozycja i sposób leczenia depresji i psychozy u ludzi |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17181057T PL3263108T3 (pl) | 2012-07-12 | 2013-07-09 | Kompozycja i sposób leczenia depresji i psychozy u ludzi |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9737531B2 (pl) |
| EP (2) | EP3263108B1 (pl) |
| JP (2) | JP6416762B2 (pl) |
| CN (2) | CN107875389B (pl) |
| AU (2) | AU2013288827B2 (pl) |
| CA (1) | CA2878565A1 (pl) |
| DK (1) | DK2872139T3 (pl) |
| ES (2) | ES2657895T3 (pl) |
| HU (1) | HUE038023T2 (pl) |
| IL (1) | IL236687A0 (pl) |
| PL (2) | PL3263108T3 (pl) |
| PT (2) | PT2872139T (pl) |
| WO (1) | WO2014011590A2 (pl) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE407117T1 (de) | 2003-01-16 | 2008-09-15 | Acadia Pharm Inc | Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen |
| US10172810B2 (en) * | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
| KR101769999B1 (ko) | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Ｎｍｄａ 수용체 조절제 및 그의 용도 |
| EP3598971B1 (en) | 2013-01-22 | 2024-03-20 | Vistagen Therapeutics, Inc. | Dosage forms and therapeutic uses of l-4-chlorokynurenine |
| WO2014120784A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| SI2951183T1 (sl) | 2013-01-29 | 2019-07-31 | Aptinyx Inc. | Spiro-laktam NMDA receptorski modulatorji in njihove uporabe |
| US9738650B2 (en) | 2013-01-29 | 2017-08-22 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| WO2014120786A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| CN105308049A (zh) | 2013-01-29 | 2016-02-03 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| RU2721948C2 (ru) * | 2014-05-06 | 2020-05-25 | Нортвестерн Юниверсити | Комбинации соединений, модулирующих nmda-рецептор |
| CN106659763A (zh) * | 2014-08-14 | 2017-05-10 | 诺雷克斯股份有限公司 | 使用nmda调节剂治疗抑郁症的方法 |
| MX2017002775A (es) | 2014-09-15 | 2017-08-10 | Rugen Holdings (Cayman) Ltd | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. |
| US20180271869A1 (en) * | 2014-09-22 | 2018-09-27 | Jie Liu | Treatment of anxiety disorders and autism spectrum disorders |
| CA2968977A1 (en) | 2014-12-02 | 2016-06-09 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| EP3237399B1 (en) | 2014-12-23 | 2022-11-30 | Avalo Therapeutics, Inc. | Compounds, compositions and methods |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| CN107849010B (zh) | 2015-06-01 | 2021-11-09 | 卢郡控股(开曼)有限公司 | 作为nr2b nmda受体拮抗剂的3,3‐二氟哌啶氨基甲酸酯杂环化合物 |
| EP3325444B1 (en) | 2015-07-20 | 2021-07-07 | Acadia Pharmaceuticals Inc. | Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c |
| US20170119704A1 (en) * | 2015-10-13 | 2017-05-04 | Ovid Therapeutics Inc. | Treatment of cognitive impairment |
| CA3002070A1 (en) * | 2015-10-16 | 2017-04-20 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
| WO2017117514A1 (en) * | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| WO2017201283A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| SG11201810358YA (en) * | 2016-05-25 | 2018-12-28 | Mitsubishi Tanabe Pharma Corp | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| JP7032378B2 (ja) | 2016-08-01 | 2022-03-08 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| MX383650B (es) | 2016-08-01 | 2025-03-14 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos. |
| WO2018026763A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2017306158B2 (en) | 2016-08-01 | 2021-10-14 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof |
| SG11201900554YA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda modulators and methods of using same |
| JP7096813B2 (ja) * | 2016-08-26 | 2022-07-06 | エクシーバ ゲーエムベーハー | 組成物及びその方法 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| US11337932B2 (en) | 2016-12-20 | 2022-05-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| CN110087640A (zh) | 2016-12-20 | 2019-08-02 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
| US11464768B2 (en) | 2016-12-20 | 2022-10-11 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis |
| KR20190124722A (ko) * | 2017-01-31 | 2019-11-05 | 파올로 엘. 만프레디 | 신경계 장애의 치료에서 사용하기 위한 ｄ-메타돈 및 이의 유도체 |
| US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| US11478467B2 (en) | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
| JP7514078B2 (ja) * | 2017-05-04 | 2024-07-10 | エクシーバ ゲーエムベーハー | 新規な組成物、組み合わせ及びその方法を用いた標的薬物救済 |
| CN108853510B (zh) * | 2017-05-09 | 2022-05-20 | 浙江大学 | Nmdar抑制剂和t型钙离子通道抑制剂的组合对抑郁症的治疗和药物 |
| JP7312116B2 (ja) | 2017-05-25 | 2023-07-20 | グリテック， エルエルシー | 外傷後ストレス障害の治療用の製剤 |
| KR102609676B1 (ko) * | 2017-06-12 | 2023-12-05 | 글리테크 엘엘씨. | Nmda 길항제 및 d2/5ht2a 또는 선택적 5ht2a 길항제를 이용한 우울증의 치료 |
| US20200121652A1 (en) * | 2017-06-16 | 2020-04-23 | The Doshisha | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
| EP3639854A4 (en) | 2017-06-16 | 2021-03-03 | The Doshisha | MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF |
| EP3641732A1 (en) | 2017-06-21 | 2020-04-29 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
| CA3071137A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | Prodrugs of substituted heterocycle fused gamma-carbolines |
| US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
| KR102036909B1 (ko) * | 2017-11-28 | 2019-10-25 | 한국과학기술원 | 신규 디스토니아 치료용 약학적 조성물 |
| CN112204031B (zh) | 2018-01-31 | 2024-05-24 | 元羿生物科技(香港)有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| US11980617B2 (en) * | 2018-03-16 | 2024-05-14 | Intra-Cellular Therapies, Inc. | Methods of treating acute depression and/or acute anxiety |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| WO2020041504A1 (en) | 2018-08-21 | 2020-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| US11865088B2 (en) | 2018-10-05 | 2024-01-09 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| JP7649743B2 (ja) | 2018-12-21 | 2025-03-21 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP7483630B2 (ja) * | 2018-12-27 | 2024-05-15 | 国立大学法人千葉大学 | 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
| CN109464436A (zh) * | 2019-01-10 | 2019-03-15 | 高智玉 | 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用 |
| WO2020264531A1 (en) * | 2019-06-28 | 2020-12-30 | The Trustees Of The University Of Pennsylvania | Intranasal dantrolene administration for treatment of alzheimer's disease |
| US12478623B2 (en) | 2019-09-25 | 2025-11-25 | Intra-Cellular Therapies, Inc. | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| JP7261942B2 (ja) | 2019-12-11 | 2023-04-20 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260324A (en) | 1990-02-06 | 1993-11-09 | G. D. Searle & Company | Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
| DE4118740A1 (de) | 1991-06-05 | 1992-12-10 | Schering Ag | Neue kombinationspraeparate zur behandlung des morbus parkinson |
| GB9208492D0 (en) | 1992-04-16 | 1992-06-03 | Glaxo Spa | Heterocyclic compounds |
| DE69334237D1 (de) | 1992-06-22 | 2008-09-25 | State Of Oregon Through Oregon | Glycinrezeptorantagonisten und ihre verwendung |
| DE4222826A1 (de) | 1992-07-09 | 1994-01-13 | Schering Ag | Arzneimittel zur Verhinderung der Toleranzentwicklung während der Behandlung mit Benzodiazepin-Rezeptor-Bindenen Wirkstoffen |
| GB9304500D0 (en) | 1993-03-05 | 1993-04-21 | Glaxo Spa | Heterocyclic compounds |
| GB9319243D0 (en) | 1993-09-17 | 1993-11-03 | Glaxo Spa | Heterocyclic compounds |
| US5801183A (en) | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
| GB9502695D0 (en) | 1995-02-11 | 1995-03-29 | Glaxo Spa | Pharmaceutical composition |
| GB9507318D0 (en) | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
| MY132385A (en) | 1995-08-31 | 2007-10-31 | Novartis Ag | 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives |
| WO1997020553A1 (en) | 1995-12-07 | 1997-06-12 | Javitt Daniel C | Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists |
| FR2743366B1 (fr) | 1996-01-10 | 1998-02-06 | Rhone Poulenc Rorer Sa | Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation, leurs intermediaires et les medicaments les contenant |
| US5728728A (en) | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
| US5776935A (en) | 1996-07-25 | 1998-07-07 | Merz & Co. Gmbh & Co. | Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission |
| GB9704499D0 (en) | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Method of manufacture |
| GB9704498D0 (en) | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Chemical compound |
| GB9706294D0 (en) | 1997-03-26 | 1997-05-14 | Glaxo Wellcome Spa | Heterocyclic compound |
| JP2001522358A (ja) | 1997-04-18 | 2001-11-13 | アボツト・ラボラトリーズ | 高純度６，７−ジクロロ−５−ニトロ−２，３−ジヒドロキノキサリン−２，３−ジオンの調製方法 |
| WO1999034790A1 (en) | 1998-01-09 | 1999-07-15 | Allelix Neuroscience, Inc. | Glycine transport inhibitors |
| DE69936848T2 (de) * | 1998-04-14 | 2008-05-15 | The General Hospital Corp., Boston | Verwendung von d-serin oder d-alanin zur behandlung von schizophrenie |
| EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| ATE407117T1 (de) | 2003-01-16 | 2008-09-15 | Acadia Pharm Inc | Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen |
| IL154318A (en) * | 2003-02-06 | 2010-05-31 | Sarah Herzog Memorial Hospital | Pharmaceutical compositions for the treatment of movement disorders |
| CA2528622C (en) | 2003-05-27 | 2010-08-03 | Forest Laboratories, Inc. | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
| GT200400213A (es) | 2003-10-22 | 2007-09-05 | Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo | |
| CA2547639A1 (en) | 2003-12-02 | 2005-06-16 | B&B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| CA2592631A1 (en) | 2003-12-29 | 2005-07-21 | Jason Mcdevitt | Compositions and methods to treat recurrent medical conditions |
| KR20070017136A (ko) | 2004-02-13 | 2007-02-08 | 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 | 정신과적 질환의 치료를 위한 ｎｍｄａ 수용체 길항제와항우울제 ｍａｏ 억제제 또는 ｇａｄｐｈ 억제제의 조합물 |
| WO2005079756A2 (en) | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| FR2873294B1 (fr) * | 2004-07-26 | 2008-05-09 | Greenpharma Sa Sa | Association de medicaments |
| US7868176B2 (en) | 2004-09-27 | 2011-01-11 | Acadia Pharmaceuticals, Inc. | Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation |
| MX2007006120A (es) * | 2004-11-23 | 2007-12-07 | Adamas Pharmaceuticals Inc | Metodo y composicion para administrar a un sujeto un antagonista del receptor de nmda. |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| US20080194698A1 (en) * | 2005-03-07 | 2008-08-14 | Michael Hermanussen | Nmda Receptor Antagonists in the Medical Intervention of Metabolic Disorders |
| EP2134330B1 (en) * | 2007-03-19 | 2013-05-08 | Acadia Pharmaceuticals Inc. | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
| IL188681A0 (en) * | 2008-01-09 | 2008-12-29 | Amino Acid Solutions Inc | Pharmaceutical compositions and methods utilizing a d-amino acid |
| US20100069399A1 (en) * | 2008-09-15 | 2010-03-18 | Auspex Pharmaceutical, Inc. | Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors |
| KR101769999B1 (ko) | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Ｎｍｄａ 수용체 조절제 및 그의 용도 |
| WO2010099217A1 (en) * | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| PL2985032T3 (pl) | 2009-10-05 | 2019-07-31 | Northwestern University | Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona |
| CN102762554A (zh) | 2010-02-16 | 2012-10-31 | 辉瑞大药厂 | 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 |
| US8735397B2 (en) * | 2010-03-29 | 2014-05-27 | Vanderbilt University | Method for treating schizophrenia and related diseases |
| EP2582366B1 (en) | 2010-06-15 | 2015-10-28 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| EP2670409B1 (en) | 2011-01-31 | 2018-04-18 | Serotech, LLC | Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder |
| MX2014010939A (es) | 2012-03-12 | 2014-11-13 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento. |
-
2013
- 2013-07-07 US US13/936,198 patent/US9737531B2/en active Active
- 2013-07-09 PT PT138166228T patent/PT2872139T/pt unknown
- 2013-07-09 PT PT171810575T patent/PT3263108T/pt unknown
- 2013-07-09 HU HUE13816622A patent/HUE038023T2/hu unknown
- 2013-07-09 EP EP17181057.5A patent/EP3263108B1/en active Active
- 2013-07-09 CN CN201711339809.7A patent/CN107875389B/zh active Active
- 2013-07-09 EP EP13816622.8A patent/EP2872139B1/en active Active
- 2013-07-09 DK DK13816622.8T patent/DK2872139T3/en active
- 2013-07-09 CA CA2878565A patent/CA2878565A1/en not_active Abandoned
- 2013-07-09 WO PCT/US2013/049653 patent/WO2014011590A2/en not_active Ceased
- 2013-07-09 PL PL17181057T patent/PL3263108T3/pl unknown
- 2013-07-09 CN CN201380037202.7A patent/CN104507477B/zh active Active
- 2013-07-09 PL PL13816622T patent/PL2872139T3/pl unknown
- 2013-07-09 AU AU2013288827A patent/AU2013288827B2/en active Active
- 2013-07-09 ES ES13816622.8T patent/ES2657895T3/es active Active
- 2013-07-09 JP JP2015521708A patent/JP6416762B2/ja active Active
- 2013-07-09 ES ES17181057T patent/ES2764746T3/es active Active
-
2015
- 2015-01-12 IL IL236687A patent/IL236687A0/en unknown
- 2015-09-03 US US14/844,021 patent/US9486453B2/en active Active
-
2017
- 2017-07-16 US US15/650,912 patent/US10660887B2/en active Active
-
2018
- 2018-05-15 AU AU2018203371A patent/AU2018203371B2/en active Active
- 2018-10-04 JP JP2018188725A patent/JP2019014740A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2657895T3 (es) | 2018-03-07 |
| DK2872139T3 (en) | 2018-02-05 |
| WO2014011590A3 (en) | 2014-02-27 |
| US9737531B2 (en) | 2017-08-22 |
| US10660887B2 (en) | 2020-05-26 |
| ES2764746T3 (es) | 2020-06-04 |
| IL236687A0 (en) | 2015-02-26 |
| US20150374684A1 (en) | 2015-12-31 |
| JP2015522075A (ja) | 2015-08-03 |
| PT3263108T (pt) | 2020-01-15 |
| WO2014011590A2 (en) | 2014-01-16 |
| JP6416762B2 (ja) | 2018-10-31 |
| US20140018348A1 (en) | 2014-01-16 |
| US20170312275A1 (en) | 2017-11-02 |
| PT2872139T (pt) | 2018-02-09 |
| AU2018203371B2 (en) | 2019-11-21 |
| EP2872139A2 (en) | 2015-05-20 |
| EP2872139A4 (en) | 2015-08-12 |
| EP3263108B1 (en) | 2019-10-02 |
| EP3263108A1 (en) | 2018-01-03 |
| PL3263108T3 (pl) | 2020-06-01 |
| CN104507477B (zh) | 2018-01-19 |
| US9486453B2 (en) | 2016-11-08 |
| AU2013288827A1 (en) | 2015-02-19 |
| CA2878565A1 (en) | 2014-01-16 |
| EP2872139B1 (en) | 2017-11-01 |
| JP2019014740A (ja) | 2019-01-31 |
| AU2013288827B2 (en) | 2018-03-08 |
| HUE038023T2 (hu) | 2018-09-28 |
| CN107875389A (zh) | 2018-04-06 |
| AU2018203371A1 (en) | 2018-06-07 |
| CN104507477A (zh) | 2015-04-08 |
| CN107875389B (zh) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL236687A0 (en) | Composition and method for the treatment of depression and psychosis in humans | |
| ZA201503332B (en) | Water treatment composition and method of using same | |
| EP2890391A4 (en) | METHOD AND COMPOSITION FOR TREATING HYPERGLYCEMIA | |
| IL238416A0 (en) | Preparations and methods for the treatment of diseases caused by protein pathology | |
| IL234792A (en) | Preparation and method of coating | |
| GB201222180D0 (en) | Vehicle and method of control thereof | |
| EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
| DK3292875T3 (en) | Compositions and methods for treating diseases | |
| GB2503842B (en) | Composition and method of manufacture | |
| GB201122195D0 (en) | Composition and method | |
| GB201408236D0 (en) | Composition and method | |
| IL234829A0 (en) | Methods and preparations for treating inflammation | |
| AP3773A (en) | Method and composition for sequestration of arsenic | |
| GB201210273D0 (en) | Vehicle and method of control thereof | |
| GB201106433D0 (en) | Composition and method | |
| EP2894964A4 (en) | COMPOSITIONS AND METHOD FOR CONTROLLING FUNGI | |
| ZA201409028B (en) | Cosmetic composition and method for using thereof | |
| ZA201502205B (en) | Ectoparasitic treatment method and composition | |
| GB201222820D0 (en) | Woolscouring method and composition | |
| ZA201409029B (en) | Cosmetic composition and method for using thereof | |
| GB201206859D0 (en) | Method and composition | |
| GB2493595B (en) | Wheelchair and method of construction | |
| ZA201500172B (en) | Plant-disease-control composition and plant-disease-control method | |
| EP2922675A4 (en) | METHOD AND APPARATUS FOR MANUFACTURING COMPOSITE ARTICLES | |
| GB201222736D0 (en) | Composition and process |